SEARCH

SEARCH BY CITATION

References

  • 1
  • 2
    Wood R, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199270.
  • 3
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 13839.
  • 4
    Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995; 333: 13017.
  • 5
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 722.
  • 6
    EURASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 55472.
  • 7
    Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of ‘statin’ lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161: 538.
  • 8
    Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and women, a reflection of the research evidence? J Clin Epidemiol 2002; 55: 95101.
  • 9
    Feely J, McGettingan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. Clin Pharmacol Ther 2000; 67: 43841.
  • 10
    Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D. Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999; 21: 604.
  • 11
    Reid FD, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002; 88: 159.
  • 12
    DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994–2001: a case of agism but not of sexism? Heart 2003; 89: 41721.
  • 13
  • 14
    Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 35662.
  • 15
    Vollset SE. Confidence intervals for a binomial proportion. Stat Med 1993; 12: 80824.
  • 16
    Svilaas A, Ose L, Risberg K, Thoresen M. Treatment goals for blood lipids in high risk patients of atherosclerotic disease. Tidsskr Nor Lægeforen 2001; 121: 105963.
  • 17
    Sueta CA, Chowdhury M, Boccuzzi SJ et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 13037.
  • 18
    Bennett KE, Williams D, Feely J. Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland. Ir Med J 2002; 95: 16972.
  • 19
    Furu K, Skurtveit S, Rosvold EO. Drug use questions in Norwegian health surveys – response rate and agreement between specific and open-ended questions. Nor J Epidemiol 2003; 13: 14754.
  • 20
    West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142: 110312.
  • 21
    Kehoe R, Wu SY, Leske MC, Chylack LT. Comparing self-reported and physician-reported medical history. Am J Epidemiol 1994; 139: 8138.
  • 22
    Graff-Iversen S, Grøtvedt L. Vekten øker, blodtrykket synker og 40-åringenes kolesterolnivå er som i 1991. Lipid forum 2003; 41: 149.
  • 23
    Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, Egger M. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990–2001. Heart 2003; 89: 3278.
  • 24
    Shepherd J, Blauw GJ, Murphy MB et al. on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 162330.
  • 25
    Bønaa KH, Thelle DS. Association between blood pressure and serum lipids in a population: the Tromsø study. Circulation 1991; 83: 130514.
  • 26
    Conroy RM, Pyörälä K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 9871003.
  • 27
    Haq IU, Ramsay LE, Yeo WW et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81: 406.
  • 28
    Hippisely-Cox J, Cater R, Pringle M, Coupland C. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 2003; 326: 68992.
  • 29
    Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 4627.
  • 30
    Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993–1998. Br J Clin Pharmacol 2002; 53: 3758.